Side-by-side · Research reference

DSIPvsFOXO4-DRI

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED8/36 cited

BAnimal-StrongHUMAN-REVIEWED12/45 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

FOXO4-DRI

Senolytic Peptide · D-Retro-Inverso

p53-TADMolecular targetBourgeois 2025

Pre-clinicalDevelopment stage

SQRoute (animal)

SQ · Animal models only

01Mechanism of Action

Parameter

DSIP

FOXO4-DRI

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

FOXO4-p53 protein complex in senescent cellsBourgeois 2025 Tripathi 2021

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021 Alameen 2026

Feedback intact?

—

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance

Antibody development

—

02Dosage Protocols

Parameter

DSIP

FOXO4-DRI

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

—

Frequency

Once daily, pre-sleep

—

Lower / starter dose

50 mcg pre-sleep

—

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Animal / mechanistic

Duration

8–12 weeks per cycle

Weeks to months (animal studies)

Senescent cell clearance observed within weeks.

Reconstitution

Bacteriostatic water

—

Timing

30–60 min pre-sleep

—

Half-life

Short plasma; CNS effects last hours

—

Animal dose (mouse)

—

5 mg/kg

SQ injection, aged mouse model (testosterone restoration).

Frequency (animal)

—

Variable — single or intermittent dosing

Protocol-dependent; no standardised regimen.

Human equivalent (theoretical)

—

~0.4 mg/kg (28 mg / 70 kg adult)

Extrapolated using allometric scaling; no clinical validation.

Route

—

SQ (animal)

No human route established.

Clinical status

—

No human trials completed

04Side Effects & Safety

Parameter

DSIP

FOXO4-DRI

Injection site reaction

Mild irritation

—

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

—

Pregnancy / OB

Avoid

—

Pulmonary hypertension risk

—

Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023

Context-dependent toxicity

—

Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023

Off-target apoptosis

—

Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)

Immune perturbation

—

Senescent cells contribute to immune surveillance; clearance effects unknown

Human safety unknown

—

No clinical trials — toxicity profile in humans not established

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

FOXO4-DRI

·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
·Pregnancy / lactation (no safety data)

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

FOXO4-DRI

·Active malignancy (senescence as tumour suppressor mechanism)
·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)

05Administration Protocol

Parameter

DSIP

FOXO4-DRI

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Subcutaneous injection used in rodent models. No human administration protocol exists.

2. Injection site

SQ — abdomen. Rotate sites.

Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.

3. Timing

30–60 min pre-sleep.

Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.

5. Needle

29–31G insulin syringe.

Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.